-
Excellent recognition of the potential of DUNP19 to treat a rare bone cancer
-
The FDA designation derives several benefits including tax breaks, user fee exemption and seven years market exclusivity post approval
-
RAD acquired the DUNP19 technology from UCLA in April 2022
-
Osteosarcoma has a significant unmet need with surgery and chemotherapy the current standard of care
Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that the US Food & Drug Administration (FDA) has granted Orphan Drug Designation for its DUNP19 technology for the treatment of osteosarcoma.
For more information, download the attached PDF.
Download this document
